Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GoodRx Holdings, Inc. - Class A Common Stock (NQ:GDRX)

3.900 -0.120 (-2.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about GoodRx Holdings, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Let's uncover which stocks are experiencing notable gaps during today's session.
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
Novo Nordisk Stock Surges After Pharma Major Cuts Ozempic Cost to $499 Per Month For Self-Paying Patients
The new offer aims to assist Type 2 diabetes patients who are uninsured or choose to self-pay, and may potentially face prices at or above wholesale cost. 
Via Stocktwits
3 Small-Cap Stocks Walking a Fine Line
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
3 Stocks Under $10 We Approach with Caution
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as... 
Via StockStory
Topics Retirement
Earnings Scheduled For August 6, 2025
 
Via Benzinga
Earnings Scheduled For May 7, 2025
 
Via Benzinga
GDRX Q2 Deep Dive: Headwinds from Rite Aid and PBM Disruptions Offset Pharma Solutions Growth
Healthcare tech company GoodRx (NASDAQ:GDRX) missed Wall Street’s revenue expectations in Q2 CY2025 as sales only rose 1.2% year on year to $203.1 million. Its non-GAAP profit of $0.09 per share was in... 
Via StockStory
Topics Bankruptcy
GoodRx (NASDAQ:GDRX) Reports Sales Below Analyst Estimates In Q2 Earnings, Stock Drops
Healthcare tech company GoodRx (NASDAQ:GDRX) missed Wall Street’s revenue expectations in Q2 CY2025 as sales only rose 1.2% year on year to $203.1 million. Its non-GAAP profit of $0.09 per share was in... 
Via StockStory
GoodRx (GDRX) To Report Earnings Tomorrow: Here Is What To Expect
Healthcare tech company GoodRx (NASDAQ:GDRX) will be reporting earnings this Wednesday after the bell. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence Economy World Trade
Curious about the stocks that are showing activity after the closing bell on Friday?
The regular session of the US market on Friday is now over, but let's get a preview of the after-hours session and explore the top gainers and losers driving the post-market movements. 
Via Chartmill
1 Healthcare Stock for Long-Term Investors and 2 to Be Wary Of
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
3 Low-Volatility Stocks Skating on Thin Ice
Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
Via StockStory
SolarEdge, GoodRx, BigCommerce, 8x8, and Angi Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +1.4%, S&P 500 +1.0%) on hopes the reported ceasefire between Israel and Iran will hold. This de-escalation... 
Via StockStory
Topics Economy Stocks
3 Cash-Producing Stocks in the Doghouse
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities. 
Via StockStory
GDRX Q1 Earnings Call: Management Focuses on Pharmacy Partnerships and Marketplace Evolution
Healthcare tech company GoodRx (NASDAQ:GDRX) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.6% year on year to $203 million. The company’s outlook for the full year was close to... 
Via StockStory
Topics Bankruptcy
3 Small-Cap Stocks Facing Headwinds
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
3 Stocks Under $10 with Mounting Challenges
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as... 
Via StockStory
Healthcare Technology Stocks Q1 Recap: Benchmarking GoodRx (NASDAQ:GDRX)
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at healthcare technology stocks, starting... 
Via StockStory
GoodRx Offers Value Proposition As Pharmacy Costs Shifts To Consumers: Analyst
J.P. Morgan analyst revises outlook on GoodRx Holdings following Q1 earnings, reaffirms Overweight rating and $7 price target. 
Via Benzinga
Demystifying GoodRx Holdings: Insights From 5 Analyst Reviews
 
Via Benzinga
Why GoodRx Holdings Stock Triumphed on Thursday
Via The Motley Fool
GoodRx’s (NASDAQ:GDRX) Q1 Earnings Results: Revenue In Line With Expectations, Stock Jumps 10.3%
Healthcare tech company GoodRx (NASDAQ:GDRX) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 2.6% year on year to $203 million. The company’s outlook for the full year was close to... 
Via StockStory
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
GoodRx (GDRX) Reports Earnings Tomorrow: What To Expect
Healthcare tech company GoodRx (NASDAQ:GDRX) will be reporting results tomorrow after the bell. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence
3 Reasons to Sell GDRX and 1 Stock to Buy Instead
GoodRx’s stock price has taken a beating over the past six months, shedding 30.4% of its value and falling to $4.55 per share. This was partly driven by its softer quarterly results and may have... 
Via StockStory
Topics Supply Chain
3 Healthcare Stocks with Questionable Fundamentals
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID... 
Via StockStory
Topics Stocks
3 of Wall Street’s Favorite Stocks Showing Warning Signs
Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional... 
Via StockStory
Healthcare Technology Stocks Q4 In Review: Hims & Hers Health (NYSE:HIMS) Vs Peers
Let’s dig into the relative performance of Hims & Hers Health (NYSE:HIMS) and its peers as we unravel the now-completed Q4 healthcare technology earnings season. 
Via StockStory
3 Small-Cap Stocks in Hot Water
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small... 
Via StockStory
3 Stocks Under $10 Skating on Thin Ice
Stocks trading in the $1-10 range are generally smaller players with less risk than their penny stock counterparts. But that doesn’t mean the underlying businesses are cheap, and we advise caution as... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.